Ebola Vaccine Trials Gives High Results

2019 ias preliminary exam test series

The United Nations World Health Organization (WHO) has informed that an experimental Ebola vaccine has been found to be highly protective against the deadly virus in a major trial in Guinea.

According to WHO, the vaccine, rVSV-ZEBOV was studied in a trial involving 11,841 people in Guinea during 2015.

Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.

The Ebola virus was first identified in 1976 and caused sporadic outbreaks in Africa. However, the 2013-2016 outbreak in west Africa, that killed more than 11,300 people, underlined the urgent need of a vaccine.

Guinea, along with Liberia and Sierra Leone, was one of the worst affected countries.

The trial took place in the coastal region of Basse-Guinée, the area of Guinea still experiencing new Ebola cases when the trial started in 2015.

It employed an innovative design, a so-called “ring vaccination” approach – the same method used to eradicate small pox. This involved tracing all people who may have been in contact with a new Ebola case within the previous three weeks as well as certain “contacts of contacts.”

Current Affairs for IAS Exam